Oncology / Haematology
A Phase III Randomised, double blind, placebo controlled, multicentre study evaluating the efficacy and safety of GDC-9545 combined with Palbociclib in women with estrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer.
|Trial Name: persevERA||PI: Dr Jacquelyn Thomson|
Who can take part:
- Patient has breast cancer that is positive for ER, and HER2-negative locally advanced (recrurrent or progressed) or metastatic breast cancer.
- Disease recurrence during or within 12 months of completing prior neoadjuvant or adjuvant treatment with an AI
- Disease recurrence during or within 12 months of completing prior neoadjuvant or adjuvant treatment with any CDK4/6 inhibitor
- Prior treatment with a SERD
For further information please contact Diane Canning – 03 9784 8224
Non-drug Phase 1 Phase 2 Phase 3 Phase 4